In HBV-related cirrhosis patients, gut microbiota dysbiosis amplifies systemic inflammation and lipid metabolic disturbances through gut-liver axis interactions, potentially impairing insulin-mediated glucose regulation (Shi et al., 2025). The gene discussed is INS; the disease is Cirrhosis.